2022
Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B, Wagner-Golbs A. Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2022, 17: s31-s32. DOI: 10.1055/s-0042-1746295.Peer-Reviewed Original Research
2021
Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial
Inzucchi, Zinman B, Wanner C, Fitchett D, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51-s52. DOI: 10.1055/s-0041-1727465.Peer-Reviewed Original ResearchEmpagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
Fitchett D, Inzucchi, Zinman B, Wanner C, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51. DOI: 10.1055/s-0041-1727464.Peer-Reviewed Original ResearchEmpagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial
Vaduganathan M, Sattar N, Fitchett D, George J, Ofstad A, Verma S, Mattheus M, Wanner C, Inzucchi, Zinman B, Butler J. Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s18-s19. DOI: 10.1055/s-0041-1727336.Peer-Reviewed Original ResearchEffect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial
Hamilton A, Fitchett D, Zinman B, Inzucchi S, Wanner C, Anker S, Pocock S, Kaspers S, Mattheus M, Vedin O, Hantel S, Lund S. Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s220-s221. DOI: 10.1016/j.hlc.2021.06.278.Peer-Reviewed Original ResearchAssociation of Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Insights From the EMPA-REG OUTCOME Trial
Hamilton A, Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. Association of Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Insights From the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s212-s213. DOI: 10.1016/j.hlc.2021.06.259.Peer-Reviewed Original Research
2020
1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial
NEELAND I, ELIASSON B, KASAI T, MARX N, ZINMAN B, INZUCCHI S, WANNER C, ZWIENER I, WOJECK B, YAGGI H, JOHANSEN O. 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1128-p.Peer-Reviewed Original ResearchObstructive sleep apneaNew-onset obstructive sleep apneaCardiovascular diseaseDohme Corp.Novo Nordisk A/SMundipharma InternationalMerck SharpEli LillyEMPA-REG OUTCOMEIncident obstructive sleep apneaFavorable metabolic effectsSanofi-AventisSystolic blood pressureCoronary artery diseaseType 2 diabetesAdvisory PanelEMPA-REGOSA statusPhilips RespironicsSanofi GenzymeSevere obesityArtery diseaseBlood pressureWaist circumferenceSleep apnea
2019
248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
INZUCCHI S, ZINMAN B, GEORGE J, MATTHEUS M, EYNATTEN M, WANNER C, HAUSKE S. 248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial. Diabetes 2019, 68 DOI: 10.2337/db19-248-or.Peer-Reviewed Original ResearchNon-proteinuric chronic kidney diseaseEffect of empagliflozinChronic kidney diseaseCardiorenal outcomesBoehringer Ingelheim PharmaceuticalsEMPA-REGCV deathKidney diseaseJanssen PharmaceuticalsEli LillyAdverse cardiorenal outcomesComposite kidney outcomeLower proteinuria levelsPrior CV diseaseSubgroup of patientsStrong risk predictorType 2 diabetesAdvisory PanelCKD populationKidney outcomesOvert albuminuriaOvert proteinuriaCause mortalityCV diseaseLower eGFR
2018
124 Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial
Verma S, Mazer C, Fitchett D, Inzucchi S, George J, Pfarr E, Woerle H, Zinman B. 124 Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial. Canadian Journal Of Diabetes 2018, 42: s43. DOI: 10.1016/j.jcjd.2018.08.129.Peer-Reviewed Original ResearchP5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, George J, Elsasser U, Woerle H, Lund S, Fitchett D. P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. European Heart Journal 2018, 39: ehy566.p5334. DOI: 10.1093/eurheartj/ehy566.p5334.Peer-Reviewed Original Research